TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07675811: A Randomized, Double-Masked, Placebo-Controlled, Phase 3 Study to Assess the Efficacy and Safety of Fel d 1 Monoclonal Antibodies in Participants With Allergic Conjunctivitis Due to Cat Allergy

Sponsor: Regeneron Pharmaceuticals · Phase: PHASE3 · Area: IMMUNOLOGY · Target Enrollment: 570 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$15,676,800

Rescue Site Savings

+$10,336,890

Unlock Full NCT07675811 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07675811 Rescue Dossier →